| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S16170 R69669 |
Hernandez-Diaz (Topiramate) (Epilepsy), 2024 | Autism spectrum disorder (ASD) - At least two visits with codes for ASD - Median follow-up was 2 years | 2nd and/or 3rd trimester | retrospective cohort (claims database) | unexposed, sick | Adjustment: Yes | 0.75 [0.37;1.52] | -/623 102/8,815 | - | 623 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S17420 R73139 |
Madley-Dowd_SE (Topiramate) (Controls exposed to LTG) (Mixed indications), 2024 | Autism - ICD-8/9/10 codes - Mean 5-20 years old (according groups) | during pregnancy (anytime or not specified) | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: Yes Partial overlapping |
1.52 [0.86;2.69] excluded (control group) |
13/264 134/5,035 | 147 | 264 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S17421 R73145 |
Madley-Dowd_SE (Topiramate) (Controls unexposed, general pop) (Mixed indications), 2024 | Autism - ICD-8/9/10 codes - Mean 5-20 years old (according groups) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed (general population or NOS) | Adjustment: Yes Partial overlapping | 1.26 [0.73;2.18] | 13/264 68,788/2,651,210 | 68,801 | 264 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S17422 R73151 |
Madley-Dowd_SE (Topiramate) (Controls unexposed, sibling) (Mixed indications), 2024 | Autism - ICD-8/9/10 codes - Mean 5-20 years old (according groups) | during pregnancy (anytime or not specified) | population based cohort retrospective | sibling excluded | Adjustment: Yes Partial overlapping |
1.95 [0.64;5.98] excluded (control group) |
-/- -/- | - | - |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S17285 R72398 |
Madley-Dowd_UK (Topiramate) (Controls exposed to LTG) (Mixed indications), 2024 | Autism - ICD10 codes - Median follow up 5.41 (3.59-8.40) years old | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: Yes |
0.28 [0.04;2.15] excluded (control group) |
-/154 20/939 | - | 154 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S17270 R72399 |
Madley-Dowd_UK (Topiramate) (Controls unexposed, general pop) (Mixed indications), 2024 | Autism - ICD10 codes - Median follow up 5.41 (3.59-8.40) years old | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: Yes | 0.31 [0.04;2.21] | -/154 7,657/514,066 | - | 154 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S17278 R72400 |
Madley-Dowd_UK (Topiramate) (Controls unexposed, sibling) (Mixed indications), 2024 | Autism - ICD10 codes - Median follow up 5.41 (3.59-8.40) years old | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | sibling excluded | Adjustment: Yes |
0.31 [0.03;3.01] excluded (control group) |
-/- -/- | - | - |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S12715 R48029 |
Bjørk (Topiramate) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2022 | Diagnosis of childhood autism (F84.0), atypical autism (F84.1), and Asperger syndrome (F84.5) - Median follow up topiramate 5.7 (2.9-9.1) years old | during pregnancy (anytime or not specified) | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No |
2.51 [1.36;4.63] C excluded (control group) |
12/471 82/7,950 | 94 | 471 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S12716 R48030 |
Bjørk (Topiramate) (Controls unexposed NOS) (Mixed indications), 2022 | Diagnosis of childhood autism (F84.0), atypical autism (F84.1), and Asperger syndrome (F84.5) - Median follow up topiramate 5.7 (2.9-9.1) years old | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed (general population or NOS) excluded | Adjustment: Yes |
2.64 [1.50;4.65] excluded (control group) |
12/471 38,437/4,463,879 | 38,449 | 471 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S12718 R48031 |
Bjørk (Topiramate) (Controls unexposed, sick) (Mixed indications), 2022 | Diagnosis of childhood autism (F84.0), atypical autism (F84.1), and Asperger syndrome (F84.5) - Median follow up topiramate 5.7 (2.9-9.1) years old | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, sick | Adjustment: No Controls: epilepsy indication | 2.09 [1.16;3.76] C | 12/471 267/21,634 | 279 | 471 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S10103 R46456 |
Coste (Topiramate) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2020 | Diagnosis Pervasive developmental disorders (F84) (mean age of 3.7 years old) | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: Yes |
0.55 [0.07;4.31] C excluded (control group) |
1/477 11/2,916 | 12 | 477 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8613 R46457 |
Coste (Topiramate) (Controls unexposed, NOS) (Mixed indications), 2020 | Diagnosis Pervasive developmental disorders (F84) (mean age of 3.6 years old) | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: Yes | 0.70 [0.10;4.70] | 1/477 4,280/1,710,441 | 4,281 | 477 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9959 R46460 |
Bjørk (Topiramate) (Controls exposed to Lamotrigine, sick), 2018 | Autistic traits at 18 months and/or at 36 months (M-CHAT <2/6 critical or <3/23 or SCQ >13) | during pregnancy (anytime or not specified) | population based cohort propective | exposed to other treatment, sick excluded | Adjustment: No |
0.97 [0.10;9.00] C excluded (control group) |
1/6 13/76 | 14 | 6 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9954 R46461 |
Bjørk (Topiramate) (Controls unexposed, disease free), 2018 | Autistic traits at 18 months and/or at 36 months (M-CHAT <2/6 critical or <3/23 or SCQ >13) | during pregnancy (anytime or not specified) | population based cohort propective | unexposed, disease free excluded | Adjustment: No |
1.99 [0.23;17.00] C excluded (control group) |
1/6 6,907/75,497 | 6,908 | 6 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9956 R46462 |
Bjørk (Topiramate) (Controls unexposed, sick), 2018 | Autistic traits at 18 months and/or at 36 months (M-CHAT <2/6 critical or <3/23 or SCQ >13) | during pregnancy (anytime or not specified) | population based cohort propective | unexposed, sick | Adjustment: No | 1.81 [0.20;16.11] C | 1/6 27/272 | 28 | 6 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8591 R46459 |
Wood (Topiramate), 2015 | Score >30 (CARS) | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick | Adjustment: No | 17.00 [0.13;2166.90] C | 0/1 0/9 | 0 | 1 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 7 studies | 1.22 [0.77;1.93] | 73,389 | 1,996 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Topiramate) (Epilepsy; 2: Topiramate) (Controls unexposed, general pop) (Mixed indications; 3: Topiramate) (Controls unexposed, general pop) (Mixed indications; 4: Topiramate) (Controls unexposed, sick) (Mixed indications; 5: Topiramate) (Controls unexposed, NOS) (Mixed indications; 6: Topiramate) (Controls unexposed, sick; 7: Topiramate;
Asymetry test p-value = 0.7996 (by Egger's regression)
slope=0.3328 (0.3961); intercept=-0.2361 (0.8819); t=0.2678; p=0.7996
excluded 9959, 9954, 10103, 12715, 12716, 17420, 17422, 17285, 17278